GSK-101197 (DTPa -127)

An open, multicentric, phase IV clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis vaccine (Infanrix™) administered to healthy infants at 2, 4 and 6 months of age.
Diphtheria, Tetanus, Acellular Pertussis Vaccine Adsorbed
101197 (DTPa -127)
Acellular pertussis; Diphtheria; Tetanus
Phase 4
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013